Goldman Sachs Raises Price Target for Mirion Technologies
Goldman Sachs has recently increased its price target for Mirion Technologies (NYSE:MIR) to $16.00, up from the previous target of $13.00, while keeping a Buy rating on the stock. This change signifies a positive outlook regarding the momentum in the nuclear new builds sector, which is expected to play a crucial role in the company's growth.
Third Quarter Performance
During the third quarter, Mirion Technologies reported an adjusted EBITDA of $46 million. This figure fell short of expectations, as both Goldman Sachs and FactSet had estimated slightly higher results, with a $2 million and $3 million difference, respectively. The main reason for this shortfall was due to stronger margins in the Technologies segment being countered by a weakening performance in its Medical division along with increased corporate expenses.
Interestingly, the company experienced a year-over-year decline of 30% in orders, a trend that was somewhat anticipated following the strong bookings seen in the third quarter of the previous year.
Contractual Challenges and New Opportunities
Mirion faced a significant setback when it had to de-book half of the $21 million Turkish new build award due to contractual disputes. However, the company also demonstrated resilience by securing two significant contracts related to the Sizewell C project, which resulted in $30 million worth of orders shifting from the second to the third quarter.
There’s also encouraging news regarding Mirion's forward-looking projects, with an active bid pipeline valued between $300-$400 million for larger projects, which the company anticipates s? convert into confirmed orders by the close of 2025.
Future Earnings Projections
Mirion Technologies reaffirmed its guidance for full-year 2024 adjusted EBITDA, expecting figures to fall between $195 million and $205 million, alongside a forecasted earnings per share (EPS) in the range of $0.37 to $0.42. Goldman Sachs views these targets as attainable, predicting an EBITDA of $201 million for the fiscal year 2024.
Moreover, the firm expresses optimism regarding the nuclear new build sector's growth, highlighting that the forthcoming investor day scheduled for December could serve as a positive catalyst for Mirion's share performance. With the revised price target of $16, there's an implied free cash flow yield of approximately 3% by the year 2026.
Revenue and Market Growth
Recent financials from Mirion illustrate an 8% growth in revenue, totaling $207 million during the third quarter. The company also reported an adjusted EPS of $0.08. Despite the 30% year-over-year decline in third-quarter orders, significant growth has been recorded in both the nuclear power sector and cancer care markets, driven by collaborations with leading technology firms and advancements in radiopharmaceutical therapies.
Adjusted metrics showcase a healthy 13% growth during the same time frame. Furthermore, Mirion's backlog currently stands at $815 million, up 2% compared to last year, reflecting a robust pipeline, particularly within the nuclear segment.
Operational Efficiency and Market Outlook
Looking ahead, Mirion anticipates consistent growth and improvements in margins, thanks to operational efficiencies. There's a considerable optimism for the Small Modular Reactor (SMR) sector, with expectations for substantial revenue growth as we approach the 2030s. Nevertheless, geopolitical factors have prompted de-bookings on some projects — a situation that may influence the industry's landscape, particularly in relation to the ongoing conflict in Ukraine.
InvestingPro Insights on Mirion Technologies
The recent performance and outlook for Mirion Technologies gain additional insight through data from InvestingPro. Reflecting strong investor faith, the company's market capitalization is pegged at $3 billion. This aligns with Goldman Sachs' bullish outlook and adjusted price target.
According to InvestingPro insights, the company's net income is poised for growth this year, further buttressing the optimistic sentiment noted in various reports. Additionally, the strong financial position of Mirion is showcased by its liquid assets exceeding its short-term obligations, providing a solid foundation for ongoing initiatives and prospective new contracts in the nuclear landscape.
Over the past year, Mirion Technologies has experienced an impressive total return of 103.62%, illustrating substantial market optimism regarding its future initiatives in the expanding nuclear new build sector.
Frequently Asked Questions
What is the new price target for Mirion Technologies?
The new price target for Mirion Technologies, as set by Goldman Sachs, is $16.00, increased from the previous target of $13.00.
How did Mirion Technologies perform in Q3?
In Q3, Mirion Technologies reported $46 million in adjusted EBITDA, which was slightly below market expectations due to various challenges.
What challenges did Mirion Technologies face?
Mirion faced a setback with a $21 million de-booking due to contractual disputes but also secured significant contracts for the Sizewell C project.
What is the company's outlook for 2024?
The company reaffirmed its adjusted EBITDA guidance for 2024 to be between $195 million and $205 million, with an EPS forecast between $0.37 and $0.42.
What are the prospects for Mirion Technologies in the nuclear sector?
Mirion Technologies is optimistic about growth in the nuclear sector, especially around small modular reactors, with a robust bid pipeline and strong investor confidence.
